Literature DB >> 917086

Abnormal biliary lipid composition in cystic fibrosis. Effect of pancreatic enzymes.

C C Roy, A M Weber, C L Morin, J C Combes, D Nusslé, A Mégevand, R Lasalle.   

Abstract

Because of the increased incidence of gallstones in cystic fibrosis we compared biliary lipid composition in 26 patients with cystic fibrosis, seven children with cholelithiasis but no cystic-fibrosis and 13 controls. Eighteen of the cystic fibrosis group had cholecystograms, and only one had gallstones. In 14 patients with cystic fibrosis who had stopped taking pancreatic enzymes for one week molar percentage of lipid composition accounted for by cholesterol (mean +/- S.E., 16.3 +/- 2.9) and saturation index (2.0 +/- 0.3) were comparable to values of the cholelithiasis group and higher (P less than 0.01) than those of controls. In 12 patients with cystic fibrosis taking pancreatic enzymes, molar percentage of cholesterol (8.6 +/- 1.7) and saturation index (1.0 +/- 0.1) did not differ from those of controls; in cystic fibrosis there was a preponderance of cholic over chenodeoxycholic acid both off (1.7 +/- 0.2) and on (1.9 +/- 0.3) therapy as compared to the cholelithiasis (0.7 +/- 0.1) and control (0.8 +/- 0.0) groups. The glycine/taurine ratio of conjugated bile acids were lower in enzyme-treated patients with cystic fibrosis (3.7 +/- 0.6) than in patients off treatment (6.4 +/- 1.0), but was higher (P less than 0.01) than in controls (1.8 +/- 0.2). Bile is lithogenic in untreated cystic fibrosis and responds to pancreatic enzymes.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 917086     DOI: 10.1056/NEJM197712152972401

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  23 in total

Review 1.  Control of malabsorption in cystic fibrosis.

Authors:  J M Littlewood; S P Wolfe
Journal:  Paediatr Drugs       Date:  2000 May-Jun       Impact factor: 3.022

Review 2.  Enzyme contents of pancreatic extract preparations. Are they optimal?

Authors:  S Maguire; M C Goodchild
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

Review 3.  Gastrointestinal Manifestations of Cystic Fibrosis.

Authors:  Thomas Kelly; James Buxbaum
Journal:  Dig Dis Sci       Date:  2015-02-04       Impact factor: 3.199

4.  Pathophysiological preconditions promoting mixed "black" pigment plus cholesterol gallstones in a DeltaF508 mouse model of cystic fibrosis.

Authors:  Folke Freudenberg; Monika R Leonard; Shou-An Liu; Jonathan N Glickman; Martin C Carey
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-04-29       Impact factor: 4.052

5.  Effect of dietary fat and residues on fecal loss of sterols and on their microbial degradation in cystic fibrosis.

Authors:  C Leroy; G Lepage; C L Morin; J M Bertrand; O Dufour-Larue; C C Roy
Journal:  Dig Dis Sci       Date:  1986-09       Impact factor: 3.199

6.  Ursodeoxycholic acid dissolution of gallstones in cystic fibrosis.

Authors:  B Salh; J Howat; K Webb
Journal:  Thorax       Date:  1988-06       Impact factor: 9.139

Review 7.  Cystic fibrosis--a gastroenterological cornucopia.

Authors:  P L Zentler-Munro
Journal:  Gut       Date:  1987-11       Impact factor: 23.059

8.  Conjugated bile acids in serum and secretions in response to cholecystokinin/secretin stimulation in children with cystic fibrosis.

Authors:  T A Robb; G P Davidson; C Kirubakaran
Journal:  Gut       Date:  1985-11       Impact factor: 23.059

Review 9.  Hepatobiliary complications of oral contraceptives.

Authors:  M C Lindberg
Journal:  J Gen Intern Med       Date:  1992 Mar-Apr       Impact factor: 5.128

10.  Biliary lipid compositions in cholestatic diseases of infancy.

Authors:  Y Tazawa; M Yamada; M Nakagawa; T Konno; K Tada
Journal:  Arch Dis Child       Date:  1983-10       Impact factor: 3.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.